The short term safety of<scp>COVID</scp>‐19 vaccines in Australia:<scp>AusVaxSafety</scp>active surveillance, February – August 2021

Abstract

AusVaxSafety active surveillance affirms the short term safety profile of Comirnaty and Vaxzevria vaccines in a large population sample during the first six months of the Australian COVID-19 vaccination program.